# Residual Plasma Concentration of Sorafenib and Adverse Events in CHC

> **NCT03340636** · — · UNKNOWN · sponsor: **University Hospital, Caen** · enrollment: 60 (estimated)

## Conditions studied

- Advanced or Metastatic Hepatocellular Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03340636
- **Lead sponsor:** University Hospital, Caen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01
- **Primary completion:** 2019-01
- **Final completion:** 2019-03
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03340636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03340636, "Residual Plasma Concentration of Sorafenib and Adverse Events in CHC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03340636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*